Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Pharmaceutical Contract Win

14 Jan 2009 07:00

RNS Number : 5695L
Imaginatik PLC
14 January 2009
 



14 January 2009

Imaginatik Plc

("Imaginatik" or the "Company")

Pharmaceutical Contract Win

Imaginatik plc (AIM: IMTK), a leading provider of cost reduction, process improvement and collaborative innovation software and processes, is pleased to announce it has secured an annual contract with one of the world's leading pharmaceutical companies.

The annual contract, for 5,000 seats, is further evidence of the Company's strong presence within the pharmaceutical industry with the new client joining the likes of Pfizer, Merck, Novartis and Solvay on Imaginatik's client list. Imaginatik now provides its collaborative software to six of the world's top pharmaceutical companies, assisting those companies in harnessing the knowledge of their thousands of employees to identify potential new products, areas of cost-reduction and process enhancements. 

Under the terms of the contract, Imaginatik will be implementing its core product, Idea Central, across a number of divisions within the client, including Research, Prescription Medicine and IT. Idea Central will play a key role in delivering process and product improvement within these divisions.

A spokesperson for the client commented, "In furthering our emphasis on Value through Innovation, Imaginatik's Idea Central provided a focal point for idea generation and sharing, streamlined our reviewing process, and served as a vehicle for ongoing communication. We found Imaginatik's software and services to be particularly effective."

Mark Turrell, CEO of Imaginatik plc commented, "We are delighted to see the investment placed on strengthening our sales team being rewarded with significant annual contract wins which add to our increasingly impressive recurring revenue figure. This contract also once again demonstrates the value of our collaborative software to the pharmaceutical industry and we are confident that this will continue to be an excellent vertical for Imaginatik going forward."

For further information please contact:

Imaginatik plc

Tel: 020 7917 2975

Mark Turrell, CEO / Shawn Taylor, CFO

WH Ireland Limited

Tel: 0121 265 6330

Tim Cofman / Katy Birkin

ICIS

Tel: 020 7651 8688

Caroline Evans-Jones / Mike Smith

About Imaginatik

Imaginatik is the leading provider of cost reduction, process improvement and collaborative innovation software and processes to the world's leading companies. More than 100 clients rely on Imaginatik's software, consulting and research to enable their best-of-breed innovation activities.

Named as a World Economic Forum Technology Pioneer for 2008 and a finalist for the IBM Lotus Awards 2008 in the Best Industry Solution category, Imaginatik's software and consulting services have helped clients discover significant sources of additional revenue, as well as tangible cost savings, process improvements and increased product pipeline. Imaginatik is also committed to developing strategic solutions in the field of innovation, working with academic institutions such as the London Business School and the Cass School of Business, London, as well as leading practitioners of corporate innovation.

For further information please visit www.imaginatik.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUOOVRKORAAAR
Date   Source Headline
28th Jul 20154:07 pmRNSHolding(s) in Company
24th Jul 201512:50 pmRNSHolding(s) in Company
21st Jul 20155:31 pmRNSHolding(s) in Company
20th Jul 20157:00 amRNSSubscription and Director Dealings
15th Jul 20157:00 amRNSFinal Results
10th Jul 20159:23 amRNSHolding(s) in Company
1st Jul 20157:00 amRNSContract Win
29th Jun 20155:11 pmRNSHolding(s) in Company
29th Jun 20155:10 pmRNSHolding(s) in Company
29th Jun 201510:30 amRNSHolding(s) in Company
25th Jun 20157:00 amRNSHolding(s) in Company
25th Jun 20157:00 amRNSHolding(s) in Company
23rd Jun 20155:15 pmRNSHolding(s) in Company
23rd Jun 20157:00 amRNSHolding(s) in Company
22nd Jun 20157:00 amRNSMarket Update
1st Jun 20152:38 pmRNSResult of General Meeting
15th May 20157:00 amRNSPosting of Circular
14th May 20157:00 amRNSProposed Issue of Equity
13th Apr 20157:00 amRNSContract Wins
30th Mar 20157:00 amRNSContract Extension
16th Feb 20157:00 amRNSContracts win
11th Feb 20158:05 amRNSTrading Update
19th Jan 20157:00 amRNSDirector Loan
22nd Dec 201410:30 amRNSGrant of Options
17th Dec 20147:00 amRNSFive Year Contract Win
16th Dec 20147:00 amRNSContract Win
8th Dec 20147:00 amRNSInterim Results
19th Nov 20147:00 amRNSDirectorate Change
14th Nov 201411:52 amRNSBlocklisting Interim Review
24th Oct 20147:00 amRNSIssue of Equity/Director's Dealing
7th Oct 20145:04 pmRNSDirector/PDMR Shareholding
27th Aug 201410:50 amRNSHolding(s) in Company
21st Aug 20141:31 pmRNSDirector/PDMR Shareholding
18th Aug 20141:37 pmRNSHolding(s) in Company
14th Aug 20141:38 pmRNSResult of AGM
22nd Jul 20147:00 amRNSProposed Share Consolidation and Notice of AGM
1st Jul 20147:00 amRNSFinal Results
16th May 201411:40 amRNSHolding(s) in Company
15th May 20148:50 amRNSBlocklisting Interim Review
13th May 201411:47 amRNSHolding(s) in Company
12th May 20144:14 pmRNSResult of General Meeting and Exercise of Options
25th Apr 20147:00 amRNSProposed Placing and Subscription
14th Apr 20147:00 amRNSContract Wins and Trading Update
18th Mar 20147:00 amRNSContract Wins
28th Feb 201410:35 amRNSDirector's Dealing
26th Feb 201412:39 pmRNSDirector's Dealing
19th Dec 20133:38 pmRNSHolding(s) in Company
18th Dec 20137:00 amRNSExercise and Grant of Options
13th Dec 20137:00 amRNSContract Extension
3rd Dec 20137:00 amRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.